Androgenetic Alopecia: Symptoms and Treatment in Men and Women

What happens to the hair follicles?

A healthy scalp continually produces, rests and sheds hairs. In androgenetic alopecia, affected follicles undergo miniaturisation: they produce progressively finer, shorter hairs that provide less coverage. You may notice more scalp showing even without dramatic amounts of hair in the shower.

This is a non-scarring form of hair loss. The underlying process differs from diseases that destroy follicles through inflammation and scarring. It also differs from alopecia areata, an autoimmune condition that often causes distinct bald patches, and telogen effluvium, which causes increased shedding after a trigger.

A daily hair count cannot distinguish these diagnoses. If you are unsure which pattern applies, our guide to the different types of alopecia explains the broader possibilities and when to seek medical assessment.

What causes androgenetic alopecia?

Genetic susceptibility and DHT in men

Several genes influence susceptibility; inheritance can come from either side of the family. Having a relative with baldness increases the likelihood, but does not establish the exact age of onset, eventual pattern or speed of progression.

Dihydrotestosterone, or DHT, is formed from testosterone through the action of 5-alpha-reductase enzymes. In susceptible scalp follicles, androgen signalling contributes to shorter growth phases and miniaturisation. Pattern hair loss does not, by itself, prove that your blood testosterone or DHT is unusually high. Local follicular sensitivity matters.

The separate article on DHT and hair loss examines the mechanism and the limits of hormone testing.

The main cycle phases are anagen, when hair grows; catagen, a short transition; and telogen, a resting phase. Shedding is also described as exogen. These stages explain why treatment effects emerge over months rather than days, but phase lengths vary between follicles and individuals.

Why female pattern hair loss needs its own assessment

Female pattern hair loss also involves follicular miniaturisation and inherited susceptibility. Its hormonal biology is not fully explained by the mechanism of male baldness. Many affected women do not have evidence of excess circulating androgens.

A clinician may investigate further when thinning is accompanied by irregular periods, new excessive facial hair, acne or other signs suggesting a hormonal disorder such as polycystic ovary syndrome. Those symptoms matter more than assuming that every woman with a widening parting needs the same hormone tests.

Changes around menopause may make thinning more noticeable. Shedding after childbirth, however, is commonly telogen effluvium and should not automatically be labelled androgenetic alopecia. Both conditions can coexist. A sudden change in an otherwise slowly evolving pattern is a reason to review the diagnosis.

What are the early signs, and when can it start?

Pattern hair loss can begin after puberty and becomes more common with age. Age, population and how studies define thinning all influence prevalence estimates.

In men, early signs often include a gradually receding hairline, reduced density near the temples or a more visible crown. In women, the parting may widen and the hair over the top of the scalp may become less dense while the frontal hairline remains relatively preserved. Complete scalp baldness is unusual in female pattern hair loss.

Progression can be slow, and it is not identical in every person. Comparing photographs taken months apart under similar lighting is more informative than checking the hairline repeatedly each day. Earlier assessment gives you time to discuss preservation options before a large change in coverage has occurred.

Pain, burning, significant redness, pustules or smooth new patches are not features to dismiss as ordinary pattern thinning. Seek medical advice about these changes, particularly if loss is progressing quickly or affects the eyebrows as well as the scalp.

How is androgenetic alopecia diagnosed?

Diagnosis usually combines the history, distribution of thinning and scalp examination. A clinician asks about progression, family history, medicines, recent illnesses, diet and other symptoms. The scalp often looks otherwise normal in uncomplicated pattern hair loss.

What the Norwood and Ludwig scales show

The Norwood scale describes seven main stages of male pattern hair loss, with variants. Earlier stages concern recession, while more extensive stages involve the frontal scalp and crown with diminishing hair between them. Not everyone moves through each stage in the same order or at the same speed.

The classic Ludwig scale has three grades, describing increasing loss of coverage over the crown and top of the scalp in women, usually with a preserved frontal fringe. Other systems describe different female patterns. A classification records appearance; it does not determine a prescription or a transplant graft count by itself.

Trichoscopy and additional investigations

Trichoscopy uses magnification to examine the scalp and hair shafts. Differences in hair diameter and the presence of miniaturised hairs can support a diagnosis.

Blood tests are selected according to the history and examination. For example, a clinician may investigate iron deficiency or thyroid disease when diffuse shedding or other symptoms suggest them. Hormone tests can be appropriate for signs of androgen excess. A biopsy is sometimes needed when the diagnosis is uncertain or a scarring disorder is suspected.

The purpose is to answer a practical question: is androgenetic alopecia the main cause, and is anything else contributing? That answer determines whether treatment should focus on follicular miniaturisation, a separate medical problem, or both.

Which treatments work for androgenetic alopecia?

Preserving existing hair is a valid treatment benefit, even when regrowth is modest. A treatment plan should state whether the aim is slower progression, improved density, cosmetic coverage or a combination. Discuss likely benefits, side effects, cost and the effort needed to continue treatment.

Option	Main role
Topical minoxidil	Supports hair regrowth
Oral finasteride 1mg	Reduces DHT levels
Other prescribed medicines	For selected cases only
Hair transplantation	Redistributes donor hair
PRP / light therapy	Possible adjunct treatment
Wigs or hairpieces	Cosmetic coverage only

Topical minoxidil

Topical minoxidil can help some men and women maintain or improve hair density. Choose a product suitable for your situation and follow its instructions: licensing and frequency depend on the formulation. Apply it to the scalp as directed, rather than assuming that more product produces faster growth.

Initial shedding can occur when treatment starts. Irritation, dryness or unwanted hair growth outside the application area are possible. Ask a pharmacist or clinician about persistent irritation and do not apply it to damaged or inflamed scalp without advice. Stop minoxidil and seek medical advice if you develop chest pain, dizziness, palpitations or swelling of the hands or feet. Check the product leaflet for other reasons to stop treatment and obtain advice.

Do not judge treatment after a few applications. Visible change usually takes several months, and a fuller assessment may require six to twelve months depending on the treatment and clinical plan. If minoxidil is stopped, its benefit generally diminishes. Pregnancy plans and breastfeeding should be discussed before treatment; minoxidil is generally avoided in these circumstances.

Finasteride and other prescribed options

Finasteride 1 mg is an oral prescription treatment for male pattern hair loss. It reduces the conversion of testosterone to DHT. It can slow progression and improve growth in some men, but it does not guarantee restoration of a youthful hairline.

Discuss sexual and psychiatric adverse effects before starting finasteride. The MHRA warns about depressed mood, depression, suicidal thoughts and sexual dysfunction, which may persist after treatment stops. For finasteride 1 mg, its advice is to stop treatment and contact a healthcare professional promptly if depression or suicidal thoughts develop. Seek emergency help if there is immediate danger.

Other options sometimes considered by prescribers include low-dose oral minoxidil or, for selected women, spironolactone. These are not licensed specifically for pattern hair loss in the UK. Oral minoxidil can affect blood pressure and cause fluid retention or increased body hair; spironolactone has pregnancy restrictions and can affect potassium levels. The need for monitoring depends on the medicine and individual risk factors.

A clinician may discuss combining treatments when the likely benefit justifies the additional burden and risks. Comparisons between medicines are not a substitute for personal assessment, and results from studies in men should not be assumed to apply equally to women.

How should response be reviewed?

Agree a baseline and a follow-up interval before starting. Consistent photographs of the parting, hairline and crown can help distinguish a real change from differences in lighting or styling. Review tolerability as well as density: a treatment that is difficult to use consistently may need adjustment.

If the response is disappointing, check the diagnosis, actual duration of treatment, regularity of use and any additional shedding trigger. Increasing doses or adding several online products without advice can add risk without solving the problem.

When is a hair transplant worth considering?

Transplantation may improve coverage when pattern hair loss is sufficiently stable and the donor area can support a realistic plan. The surgeon transfers follicles from a suitable donor region into the recipient area. Surgery does not stop androgenetic alopecia in the surrounding native hair.

A hair transplant consultation should therefore assess likely future loss, donor density, hair characteristics and long-term hairline design. Young people with rapidly changing hair loss may benefit from medical stabilisation and observation before surgery. Women with thinning throughout the donor region may have limited surgical options.

With FUE hair transplantation, follicular units are removed individually. FUT removes a strip that is then divided into grafts. FUE leaves small scars; FUT leaves a linear donor scar. Both require careful harvesting and placement.

DHI implantation refers to placing grafts with an implanter device; it is not a separate cure for androgenetic alopecia. Sapphire blades concern the instrument used to create recipient incisions. No device name guarantees density, graft survival or an absence of scarring.

Ask who performs each part of surgery, what recovery involves and how complications will be managed. Temporary shedding, swelling, infection and an unsatisfactory cosmetic result are possible. Results develop over months, and the long-term appearance also depends on what happens to the untreated hair.

What about PRP, light therapy and tissue micrografts?

Research into additional treatments has expanded, but evidence quality varies. A review by Kaiser and colleagues found encouraging results for PRP and low-level light therapy while identifying a need for better standardisation. This makes it difficult to promise the same result across clinics or devices.

Tissue micrograft approaches process small samples of the patient’s scalp for reinjection. They are different from transplantation of intact follicular units. They should not be presented as established hair cloning or a guaranteed regeneration treatment. Published research on cell-based approaches contains small, heterogeneous studies, and the long-term benefit remains uncertain.

PRP is prepared from a sample of the patient’s blood and injected into the scalp. It may be offered on its own or as an adjunct, but it requires a clinical assessment and usually a discussion of repeat sessions. Pain, redness, bruising, bleeding and infection are possible. PRP is not included in Body Expert’s standard hair transplant package; any additional treatment should be specified in the personalised quote.

Low-level light devices may improve density in some people with pattern hair loss, but protocols differ. Ask what outcome is being measured, how long treatment must continue and whether the available evidence concerns the actual device being offered. Neither PRP nor light therapy removes the need to investigate a new inflammatory scalp problem.

Cosmetic options and daily care

Wigs, hairpieces and cosmetic fibres can provide useful coverage. Their appearance depends on the product, fit and styling; they should not be dismissed as inevitably obvious or unnatural. Choosing camouflage, medication, surgery or no active treatment is a personal decision.

Scalp micropigmentation uses tattoo pigment to create the appearance of tiny hair dots. It does not restore follicles. Discuss colour, fading, future hairstyle changes and the risks of pigment reactions, infection or a result you dislike. Removal may be difficult, so avoid treating it as automatically reversible.

Gentle hair care can reduce breakage, while adequate nutrition supports general health. Neither changes inherited susceptibility by itself. Protect areas of exposed scalp from sunlight, and mention the emotional effect of hair loss during consultations if it is affecting daily life.

Common questions

Can androgenetic alopecia be reversed?

Some miniaturised hairs respond to treatment, and density may improve. There is no guaranteed cure, and longstanding loss is generally harder to reverse. Preserving coverage and slowing progression may be a more realistic goal than complete regrowth.

Does a normal hormone test rule it out?

No. Follicular susceptibility and local hormone signalling can matter even when blood tests are within their reference ranges. Diagnosis is usually based on the history and scalp findings; tests answer specific additional questions.

Can stress cause androgenetic alopecia?

Stress can be associated with a separate shedding episode, particularly telogen effluvium. That can make existing pattern thinning more noticeable. It does not mean inherited miniaturisation and temporary shedding are the same condition.

Should I wait until I have a bald patch?

You can seek advice when a persistent change in density first becomes noticeable. Assessment does not commit you to treatment. It helps establish a baseline, exclude other causes and decide whether observation, medical treatment or a later surgical discussion best fits your priorities.

Sources

Kaiser, M., Abdin, R., Gaumond, S. I., Issa, N. T., & Jimenez, J. J. (2023). Treatment of androgenetic alopecia: Current guidance and unmet needs. Clinical, Cosmetic and Investigational Dermatology, 16, 1387–1406. Read source

Krefft-Trzciniecka, K., Piętowska, Z., Nowicka, D., & Szepietowski, J. C. (2023). Human stem cell use in androgenetic alopecia: A systematic review. Cells, 12(6), 951. Read source

Goldin, J., Zito, P. M., & Raggio, B. S. (2025, August 2). Hair transplantation. In StatPearls. StatPearls Publishing. Read source

McNeil Products Ltd. (2025, January 3). Regaine for Men Extra Strength Scalp Solution 5% w/v Cutaneous Solution: Summary of product characteristics. Electronic Medicines Compendium. Read source

Gupta, M., & Mysore, V. (2016). Classifications of patterned hair loss: A review. Journal of Cutaneous and Aesthetic Surgery, 9(1), 3–12. Read source

Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2022). Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: A network meta-analysis. JAMA Dermatology, 158(3), 266–274. Read source

British Association of Dermatologists. (2024, June). Hair loss male pattern (androgenetic alopecia). Read source

British Association of Dermatologists. (2024, October). Hair loss female pattern (androgenetic alopecia). Read source

Gloucestershire Hospitals NHS Foundation Trust. (2024, January). Minoxidil for hair loss (GHPI1647). Read source

Gloucestershire Hospitals NHS Foundation Trust. (2026, July). Spironolactone for female pattern hair loss (GHPI1956). Read source

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride: Updated safety warnings for psychiatric side effects and sexual dysfunction. Read source